Cancer CouncilGo to cancer.org.au

Clinical Guidelines.

Home

Clinical Guidelines Sitemap

  • About
  • CCA guidelines
    • Barrett’s Oesophagus
    • Bowel cancer
      • Colorectal cancer
      • Surveillance colonoscopy
    • Endometrial cancer
    • Cervical cancer screening
      • Foreword
      • Introduction
      • Summary of recommendations
      • 1. Cervical cancer in Australia
      • 2. The rationale for primary HPV screening
      • 3. Terminology
      • 4. Unsatisfactory cervical screening results
      • 5. Benefits, harms and cost-effectiveness in renewed National Cervical Screening Program (NCSP)
      • 6. Management of oncogenic HPV test results
      • 7. Colposcopy
      • 8. Management of discordant colposcopic impression, histopathology and referral LBC prediction
      • 9. Management of histologically confirmed low-grade squamous abnormalities
      • 10. Management of histologically confirmed high-grade squamous abnormalities
      • 11. Management of glandular abnormalities
      • 12. HPV screening strategies for Aboriginal and Torres Strait Islander women
      • 13. Screening after total hysterectomy
      • 14. Screening in pregnancy
      • 15. Women experienced early sexual activity or victims of abuse
      • 16. Screening in immune-deficient women
      • 17. DES-exposed women
      • 18. Signs and symptoms of cervical cancer
      • 19. Psychosocial care
      • 20. Transition to the renewed National Cervical Screening Program
      • Appendices
    • Lung cancer
      • Lung cancer prevention & diagnosis
      • Lung cancer treatment
    • Prostate cancer
      • Advanced prostate cancer
      • PSA testing
    • Sarcoma
    • Skin cancer
      • Melanoma
      • Keratinocyte cancer (non-melanoma)
    • Pain management
    • Archive of CCA guidelines
    • Liver cancer
      • Hepatocellular Carcinoma
  • COSA guidelines
    • Adolescent and Young Adult (AYA) guidelines
      • AYA early cancer detection
      • AYA psychosocial management
    • Cancer therapy medication safety
    • Fertility preservation for people with cancer
      • Summary of recommendations
      • Impact on fertility
      • Discussing Risk
      • Referral and service provision
      • Psychological support
      • Options for treatment
      • Pubertal development
      • Contraception
      • Conception
      • Pregnancy
      • Appendices
    • Head and neck cancer nutrition
    • Teleoncology
    • Neuroendocrine Neoplasms (NENs)
      • Public Consultation
  • Other guidelines
  • Adolescent and Young Adult (AYA) guidelines
  • COSA guidelines for fertility preservation for people with cancer
    • Appendices
      • Additional resources
      • Guideline development process
      • COSA Fertility Preservation Guidelines Working Group
    • Conception
      • Assisted reproduction and risk of cancer recurrence
      • Interrupting hormone therapy to conceive
    • Contraception
      • Contraception after cancer treatment
      • Cancer Fertility Preservation
    • Discussing Risk
      • Health professional awareness
      • Reproductive concerns
      • Role of oncology services
    • Impact on fertility
      • Ovarian function
      • Pregnancy and live birth
      • Testicular function
    • Pubertal development
    • Options for treatment
      • Embryo cryopreservation
      • Oocyte cryopreservation
      • Safety of ovarian stimulation
      • Ovarian suppression with GnRH analogues
      • Ovarian tissue cryopreservation
      • Ovarian transposition
      • Sperm cryopreservation
      • Testicular biopsy
    • Pregnancy
      • Pregnancy and risk of cancer recurrence
      • Risk of pregnancy complications
    • Psychological support
      • Decision making
      • Fertility counselling
    • Referral and service provision
      • Referral rates and decisional conflict
      • Oncofertility service provision
      • Referral pathways
    • Summary of recommendations
  • National Cervical Screening Program
    • Appendices
      • Appendix C
      • Appendix G
      • Appendix I
      • Appendix B
      • Appendix A
      • Appendix F
      • Appendix J
      • Appendix H
      • Appendix D
      • Appendix E
    • 5. Benefits, harms and cost-effectiveness in renewed National Cervical Screening Program (NCSP)
    • 1. Cervical cancer in Australia
    • 7. Colposcopy
      • Colposcopy data for the National Cancer Screening Register
      • Supplement. Colposcopy information for discussion with patient
      • Supplement. Colposcopy technologies and documentation
      • Colposcopy terminology
      • History, examination and investigation
      • Principles of practice
      • Quality improvement in colposcopy
      • Colposcopy and treatment
    • Foreword
    • 12. HPV screening strategies for Aboriginal and Torres Strait Islander women
    • Introduction
    • Cervical Cancer Screening Guideline July 2022 Updates - PDFs
    • 8. Management of discordant colposcopic impression, histopathology and referral LBC prediction
      • Management of discordant colposcopic impression, histopathology and referral LBC prediction
      • Normal colposcopic findings following LBC prediction of Negative, LSIL or HSIL
      • Type 3 TZ (previously termed ‘unsatisfactory’) colposcopy following LBC prediction of Negative, LSIL or HSIL
    • 10. Management of histologically confirmed high-grade squamous abnormalities
      • Diagnosis of high-grade squamous abnormalities
      • Management of histologically confirmed high-grade squamous abnormalities
      • Test of Cure after treatment for HSIL (CIN2/3)
      • Treatment of high-grade squamous abnormalities
    • 11. Management of glandular abnormalities
      • Follow-up after excisional treatment for AIS
      • Investigation of cytological glandular abnormalities
      • Management of histologically confirmed high-grade glandular abnormalities
    • 9. Management of histologically confirmed low-grade squamous abnormalities
    • 6. Management of oncogenic HPV test results
      • Flowcharts: Management of oncogenic HPV test results
      • Management of HPV test results
      • Medical Services Advisory Committee recommendations for HPV testing
      • Oncogenic HPV types 16 and/or 18
      • Oncogenic HPV types not 16/18
      • Oncogenic HPV types not detected
      • Screening in women older than 75
      • Self-collected vaginal samples
      • Women undergoing exit testing
    • 19. Psychosocial care
    • 13. Screening after total hysterectomy
    • 17. DES-exposed women
    • 16. Screening in immune-deficient women
    • 14. Screening in pregnancy
    • 18. Signs and symptoms of cervical cancer
      • Investigation of abnormal vaginal bleeding
      • Investigations of other symptoms: vaginal discharge and deep dyspareunia
    • Summary of recommendations
    • 3. Terminology
      • Cytology and AMBS 2004 terminology for reporting
      • Histopathology
      • HPV testing terminology
      • Preparation of cervical screening reports
      • Supplement: Sample reports
    • 2. The rationale for primary HPV screening
    • 20. Transition to the renewed National Cervical Screening Program
    • 4. Unsatisfactory cervical screening results
    • 15. Women experienced early sexual activity or victims of abuse
  • Liver cancer clinical guidelines
    • Hepatocellular Carcinoma
  • Neuroendocrine Neoplasms (NENs) Clinical Guidelines
    • Neuroendocrine Neoplasms (NENs) Clinical Guidelines
Clinical Guidelines Sitemap
Cancer Council
Support & servicesCancer InformationGet involvedAbout usHealth professionals
Privacy PolicyAccessibilityDisclaimerSitemap